{"id":"W3084355783","doi":"10.1016/j.jtho.2020.08.022","title":"Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Genentech; National Institutes of Health; Innovent Biologics; Jounce Therapeutics; Jazz Pharmaceuticals; Varian Medical Systems; Sierra Oncology; F. Hoffmann-La Roche; Novartis; National Cancer Institute; Johnson and Johnson; AbbVie; MedImmune; Merck; GlaxoSmithKline; Spectrum Pharmaceuticals; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Common Terminology Criteria for Adverse Events; Internal medicine; Neutropenia; Oncology; Pneumonitis; Chemoradiotherapy; Radiation therapy; Progression-free survival; Surgery; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001571684,0.001908693,0.002571994,0.0005425192,0.0006167646,0.001278972,0.00117127,0.001694055,0.006600406],"category_scores_gemma":[0.001132055,0.0007584239,0.001729697,0.0004016133,0.001360694,0.001484004,0.0004779579,0.004316221,0.001186549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001480125,"about_ca_system_score_gemma":0.001977717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002077218,"about_ca_topic_score_gemma":0.005351161,"domain_scores_codex":[0.9996075,0.0001673718,0.00001454305,0.00008154527,0.00002928701,0.00009972382],"domain_scores_gemma":[0.999368,0.0001174739,0.00009434441,0.00005285539,0.00003177788,0.0003355103],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9006302,0.02951488,0.001311164,0.0006864493,0.001027281,0.00009997943,0.0001622492,0.00163573,0.01287789,0.000308856,0.002979097,0.04876629],"study_design_scores_gemma":[0.8628473,0.1303817,0.003107903,0.00002995578,0.0002958829,0.00007316383,0.00004083201,0.0007790597,0.0008523943,0.0001985354,0.00137654,0.00001659164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889048,0.002706768,0.0004865387,0.001012558,0.0003883577,0.002541857,0.00121229,0.0001392627,0.002607562],"genre_scores_gemma":[0.9807304,0.002376237,0.002307659,0.001488388,0.0003907944,0.004539877,0.002729617,0.00004903443,0.005387927],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006600406,"threshold_uncertainty_score":0.02208054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1139402507692928,"score_gpt":0.5265962188109286,"score_spread":0.4126559680416357,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}